Leadership Team
Experienced operators with deep healthcare expertise, a decade of operational track record, and a shared vision for building the world's leading regenerative medicine platform.
- ▸Co-founder with 10+ years leading BioXcellerator
- ▸Architect of vertical integration strategy
- ▸Led development of proprietary product portfolio
- ▸Driving current capital raise and international expansion
Eric Stoffers
Chief Executive Officer & Co-Founder
Eric Stoffers is the co-founder and CEO of BioXcellerator, the company he built from the ground up into the world's most advanced regenerative medicine platform. With over a decade of operational leadership in the stem cell therapy space, Eric has guided BioXcellerator through its evolution from a single clinic to a vertically integrated platform spanning clinical services, GCP-compliant manufacturing, and intellectual property development.
Eric's vision for BioXcellerator centers on vertical integration as a competitive moat — controlling the full value chain from cell sourcing and GCP-compliant manufacturing to clinical delivery and IP commercialization. Under his leadership, BioXcellerator has delivered 50,000+ stem cell applications across 170+ conditions, achieved multiple ISO certifications and Good Clinical Practices compliance, and built a proprietary product portfolio that includes Quantum MU53 Cells, NovaCells+, EVOKE Exosomes, BioX Gel, and BioX Skincare.
He is the primary architect of the company's three-entity corporate structure and the driving force behind its current capital raise and international expansion strategy.
- ▸Co-founder and board-certified physician
- ▸Oversees all clinical protocols and patient outcomes
- ▸Leads peer-reviewed publication program
- ▸Co-author of Stem Cell Secrets
Dr. Karolynn Halpert, MD
Co-Founder & Chief Medical Officer
Dr. Karolynn Halpert is a board-certified physician, co-founder of BioXcellerator, and internationally recognized expert in regenerative medicine, stem cell therapies, and integrative health. As Chief Medical Officer, she oversees all clinical protocols, patient outcomes research, and the company's scientific advisory relationships.
Dr. Halpert brings a rigorous, evidence-based approach to regenerative medicine at a time when the field is rapidly evolving. She has been instrumental in developing BioXcellerator's clinical protocols, which prioritize high-potency cell preparations, personalized treatment planning, and documented outcomes tracking — the foundation of the company's peer-reviewed publication program.
Her leadership ensures that BioXcellerator's clinical operations meet the highest international standards while continuing to push the boundaries of what is therapeutically possible with stem cell and regenerative therapies. Dr. Halpert is also a key spokesperson for the company's science and evidence narrative, representing BioXcellerator at international medical conferences. She is co-author of Stem Cell Secrets alongside Eric Stoffers.
- ▸25+ years global healthcare executive experience
- ▸Former CRO at Genomind across 18 global markets
- ▸Fortune 100 experience: Centene, Baxter, Northshore
- ▸Three-time MM&M award recipient
Beverly Tanabe
Chief Revenue Officer
Beverly Tanabe is a healthcare executive with over 25 years of global experience spanning Marketing, Communications, Sales, Strategy, Operations, Customer Experience, Business Development, and Product Development. Her leadership spans the full healthcare spectrum — from health systems and medical devices to government insurance products, pharmacogenetics, and med-tech — across companies ranging from startups to Fortune 100 organizations.
Before joining BioXcellerator, Beverly served as Chief Revenue Officer for Genomind (PGx), where she oversaw growth across the U.S. and 18 global markets. Her prior roles include Chief Growth Officer for the Mid-West Region at Centene, Chief Marketing, Sales & Communications Officer at Northshore University Health Systems, Senior Director of Marketing & Business Development for Procure Proton Therapy Centers, Director of Global Product Portfolio Optimization for Hollister Ostomy, and Senior Marketing Manager for Baxter, Biosciences Division.
Beverly holds an MBA from the University of San Francisco and is a three-time Medical Marketing and Media (MM&M) award recipient. At BioXcellerator, she leads all revenue growth initiatives, investor relations communications, and strategic partnership development.
- ▸Co-founder of CPI (Cellular Performance Institute)
- ▸Former Vice President, BrainStorm Cell Therapeutics (NASDAQ: BRTX)
- ▸Leads BioXcellerator's scientific strategy and IP development
- ▸Deep expertise in clinical-stage regenerative medicine and cell therapy
Francisco Silva
Chief Science Officer
Francisco Silva serves as Chief Science Officer of BioXcellerator, bringing a distinguished career at the intersection of regenerative medicine, biotechnology, and scientific leadership. He is a co-founder of CPI (Cellular Performance Institute) — a major competitor in the regenerative medicine space — and previously served as Vice President of BrainStorm Cell Therapeutics (BRTX), a publicly traded biopharmaceutical company focused on cell therapy for neurodegenerative diseases — giving him direct experience scaling regulated, clinical-stage regenerative medicine programs.
At BioXcellerator, Francisco leads the scientific strategy and innovation roadmap, overseeing protocol development, outcomes research, and the company's growing intellectual property portfolio. His background in clinical-stage biotech and his deep network across the regenerative medicine ecosystem position BioXcellerator at the forefront of the category — both scientifically and commercially. His involvement signals to investors that BioXcellerator's science is being built to institutional standards.
- ▸Utah Managing Partner — U.S. expansion lead
- ▸Board Member, Bioscience Americas
- ▸Healthcare finance and capital markets expertise
- ▸Oversees Utah Super Center development
Scott Frogley, DC
Utah Managing Partner & Board Member, Bioscience Americas
Scott Frogley brings deep expertise in healthcare operations, capital markets, and corporate development to BioXcellerator. As Utah Managing Partner and Board Member of Bioscience Americas, he plays a central role in the company's U.S. expansion strategy — including the Utah Super Center development and the activation of BioXcellerator's domestic market entry under Utah SB 199.
His background spans financial planning and analysis, M&A transactions, and building the operational infrastructure required to scale a vertically integrated healthcare platform. Scott is a key figure in structuring the current investment round and preparing BioXcellerator for its next phase of institutional growth.
- ▸Leads clinical, manufacturing, and administrative operations
- ▸Overseeing Utah Super Center development
- ▸BioX Health Longevity Center expansion lead
- ▸Quality systems and supply chain management
Kirk Wersland, DC
Chief Operating Officer
Kirk leads BioXcellerator's operational infrastructure with a focus on scaling the company's clinical, manufacturing, and administrative systems to support rapid growth. As COO, he is responsible for the day-to-day operational excellence that underpins BioXcellerator's quality reputation and patient outcomes.
His operational leadership spans clinic operations, supply chain management, quality systems, and the expansion of BioXcellerator's physical footprint — including the Utah Super Center development and the BioX Health Longevity Center rollout. Kirk ensures that BioXcellerator's growth does not come at the cost of the operational standards that define the brand.
Health Advisory Board
BioXcellerator's Health Advisory Board comprises internationally recognized scientists, physicians, and researchers in stem cell biology, regenerative medicine, and clinical outcomes. Their guidance ensures our protocols remain at the forefront of the science.
Full Health Advisory Board profiles, scientific credentials, institutional affiliations, and publication records are available in the Deep Dive Data Room for qualified investors.